Showing 1 - 10 of 890
We reviewed the clinical measures used in rheumatoid arthritis (RA) economic evaluations with respect to their relevance and sensitivity to changes in survival, health-related quality of life (HR-QOL) and costs. We compared the measures from the economic perspective and discussed the validity of...
Persistent link: https://www.econbiz.de/10005449252
Schizophrenia is a chronic disease that typically manifests during adolescence and early adulthood. Treatment of this disease consumes a significant proportion of the healthcare budget (billions of dollars in the US). Primary management options for schizophrenia include both pharmacologic and...
Persistent link: https://www.econbiz.de/10005404603
Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...
Persistent link: https://www.econbiz.de/10005243110
DOI: 10.2165/0019053-200826120-00008
Persistent link: https://www.econbiz.de/10005243120
Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The...
Persistent link: https://www.econbiz.de/10005243125
Treatment of adult chickenpox with aciclovir is controversial because of the relatively high cost of medication and small proven benefits of therapy. A decision-tree model was used to estimate the cost effectiveness of aciclovir, from third-party payer and societal perspectives: the incremental...
Persistent link: https://www.econbiz.de/10005243155
Objective: To compare the cost effectiveness of sequential intravenous (IV) to oral ciprofloxacin plus metronidazole (CIP/MTZ IV/PO) with that of IV ciprofloxacin plus IV metronidazole (CIP/MTZ IV) and IV imipenem-cilastatin (IMI IV) in patients with intra-abdominal infections. Design and...
Persistent link: https://www.econbiz.de/10005243176
Objective: To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard...
Persistent link: https://www.econbiz.de/10005243210
Coronary heart disease (CHD) is a major cause of death and illness in industrialised countries. Like other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, pravastatin reduces total and low density lipoprotein (LDL)-cholesterol levels and increases high density lipoprotein...
Persistent link: https://www.econbiz.de/10005243215
Background:Background: The benefit of unfractionated heparin (UFH) added to aspirin in patients with acute coronary syndromes (ACS) was described more than 20 years ago. Ever since, a wide variety of anticoagulant drugs have become available for clinical use, including low-molecular-weight...
Persistent link: https://www.econbiz.de/10009653278